Open Access

Off-Vertical Axis Rotational Assessment of Transdermal Scopolamine for Motion Sickness Prophylaxis

Daniel Woodard

Daniel Woodard

Bionetics Corporation, NASA-Kennedy Space Center
Search for this author on
Sciendo|Google Scholar
Woodard, Daniel
, 
Glenn Knox

Glenn Knox

University of Florida College of Medicine, UF Health–JacksonvilleJacksonville,
Search for this author on
Sciendo|Google Scholar
Knox, Glenn
, 
Scott Wood

Scott Wood

Department of Neurotology Research, Legacy Health SystemPortland,
Search for this author on
Sciendo|Google Scholar
Wood, Scott
 and 
Cathy DiBiase

Cathy DiBiase

Bionetics Corporation, NASA-Kennedy Space Center
Search for this author on
Sciendo|Google Scholar
DiBiase, Cathy
  
Mar 02, 2022
Off-Vertical Axis Rotational Assessment of Transdermal Scopolamine for Motion Sickness Prophylaxis's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Research Article
Published Online: Mar 02, 2022
Page range: 13 - 20
DOI: https://doi.org/10.2478/gsr-2014-0014
Keywords
© 2014 Daniel Woodard et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

JSC rotator with subject; schematic of OVAR angle.
JSC rotator with subject; schematic of OVAR angle.

Figure 2

Average symptom score (y-axis) versus elapsed time (x-axis). Series 1 is placebo, Series 2 is the 0.75 mg dose, and Series 3 is the 1.5 mg dose. Data was not collected at minute 17 since subjects egressed the chair at that time period. Data after minute 17 represents continued reporting of symptoms after the rotational stimulus was stopped. Averages of the 0–4 scale can, of course, yield non-integer values. These results were significant to the 0.05 confidence level.
Average symptom score (y-axis) versus elapsed time (x-axis). Series 1 is placebo, Series 2 is the 0.75 mg dose, and Series 3 is the 1.5 mg dose. Data was not collected at minute 17 since subjects egressed the chair at that time period. Data after minute 17 represents continued reporting of symptoms after the rotational stimulus was stopped. Averages of the 0–4 scale can, of course, yield non-integer values. These results were significant to the 0.05 confidence level.

Figure 3

Number of subjects reporting side effects at each dosage level. Note that half-dose side effects were reported by only one more subject than placebo (3 versus 2).
Number of subjects reporting side effects at each dosage level. Note that half-dose side effects were reported by only one more subject than placebo (3 versus 2).

Figure 4

Post-test nausea.
Post-test nausea.

Figure 5

Post-test fatigue.
Post-test fatigue.

j_gsr-2014-0014_tab_001

0: No abnormal sensations.
1: Abnormal sensations that do not cause noticeable discomfort, such as dizziness, unusual perspiration, and mild stomach awareness.
2: Mild discomfort, which is noticeable, but is not distracting and would not interfere, even with the performance of demanding tasks.
3: Moderate discomfort, which can be tolerated indefinitely, but is distracting and might affect one's ability to perform demanding tasks.
4: Severe discomfort, which cannot be tolerated indefinitely, or the feeling of impending vomiting.
Language:
English
Publication timeframe:
2 times per year
Journal Subjects:
Life Sciences, Life Sciences, other, Materials Sciences, Materials Sciences, other, Physics, Physics, other
Journal RSS Feed